Skip to main content
C
CorpDigest
Search

BioNTech SE

Biotechnology / ImmunotherapyFounded 2008
Reviewed by Swet Parvadiya
Company data updated: October 2026

Acquisitions

BioNTech Acquisitions

6

Major Deals Covered

$2.1B

Disclosed Deal Value

What are BioNTech's biggest acquisitions?

BioNTech's largest disclosed acquisition here is CureVac N.V. for $1.3B in 2025. This page covers 6 major deals from 2020 to 2025, each with its price where disclosed and the reason behind it.

Major deals covered
6
Largest deal
CureVac N.V. ($1.3B)
First deal
2020
Most recent
2025
CompanyYearPricePurpose
CureVac N.V.2025$1.3BBioNTech bought its Tübingen-based mRNA rival in an all-stock exchange offer to add CureVac's mRNA design, delivery and manufacturing know-how and its patent estate, months after settling U.S. patent litigation with CureVac and GSK.
Biotheus Inc.2025$800.0MBioNTech acquired the Chinese antibody developer to secure full global rights to BNT327 (PM8002, now pumitamig), a bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization, plus Biotheus's antibody discovery platform.
InstaDeep Ltd.2023UndisclosedBioNTech bought the London-based AI and machine-learning company, in which it already held a stake, to bring computational capabilities in-house for neoantigen prediction, mRNA design and drug discovery.
Kite Pharma solid-tumor TCR platform and Gaithersburg facility2021UndisclosedBioNTech acquired Gilead subsidiary Kite's solid-tumor neoantigen T-cell receptor discovery platform and its manufacturing facility in Gaithersburg, Maryland, to expand its cell therapy work in the United States.
Novartis manufacturing site in Marburg2020UndisclosedBioNTech bought the Marburg, Germany, biologics plant from Novartis in September 2020 to produce mRNA for the COVID-19 vaccine.
Neon Therapeutics2020$67.0MBioNTech acquired the Cambridge, Massachusetts neoantigen T-cell therapy company in an all-stock deal to add a U.S. R&D presence and neoantigen expertise.
What companies has BioNTech bought?
Major acquisitions by BioNTech documented here include CureVac N.V. (2025), Biotheus Inc. (2025), Neon Therapeutics (2020), InstaDeep Ltd. (2023) and Kite Pharma solid-tumor TCR platform and Gaithersburg facility (2021).
What is BioNTech's most recent acquisition?
The most recent BioNTech acquisition documented here is CureVac N.V., in 2025, for $1.3B.

CureVac N.V.

2025

$1.3B

Why

BioNTech bought its Tübingen-based mRNA rival in an all-stock exchange offer to add CureVac's mRNA design, delivery and manufacturing know-how and its patent estate, months after settling U.S. patent litigation with CureVac and GSK.

Impact

The deal closed on December 18, 2025 and ended the patent dispute between the two German mRNA companies. CureVac's operations added to BioNTech's R&D and SG&A costs in 2026.

Outcome

In September 2026 BioNTech said the former CureVac headquarters in Tübingen would close at the end of 2027 as part of its manufacturing consolidation.

Source →

Biotheus Inc.

2025

$800M

Why

BioNTech acquired the Chinese antibody developer to secure full global rights to BNT327 (PM8002, now pumitamig), a bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization, plus Biotheus's antibody discovery platform.

Impact

The deal was announced in November 2024 and closed on February 3, 2025 for $800 million, mostly in cash, plus up to $150 million in milestones. It gave BioNTech an R&D and manufacturing base in China.

Outcome

Pumitamig became BioNTech's lead oncology asset. Bristol Myers Squibb agreed in June 2025 to share it 50:50, and by August 2026 it was in seven pivotal trials.

Source →

InstaDeep Ltd.

2023

Why

BioNTech bought the London-based AI and machine-learning company, in which it already held a stake, to bring computational capabilities in-house for neoantigen prediction, mRNA design and drug discovery.

Impact

The acquisition was announced in January 2023 for about $478 million (£362 million) in cash and BioNTech shares upfront, plus up to about $264 million (£200 million) in milestones.

Outcome

InstaDeep supports BioNTech's individualized cancer vaccine and discovery work; its financial contribution is not reported separately.

Source →

Kite Pharma solid-tumor TCR platform and Gaithersburg facility

2021

Why

BioNTech acquired Gilead subsidiary Kite's solid-tumor neoantigen T-cell receptor discovery platform and its manufacturing facility in Gaithersburg, Maryland, to expand its cell therapy work in the United States.

Impact

The deal gave BioNTech a U.S. site for clinical-stage cell therapy manufacturing.

Outcome

The Gaithersburg site became part of BioNTech's U.S. cell therapy operations.

Source →

Novartis manufacturing site in Marburg

2020

Why

BioNTech bought the Marburg, Germany, biologics plant from Novartis in September 2020 to produce mRNA for the COVID-19 vaccine.

Impact

Marburg became one of BioNTech's main Comirnaty production sites during the pandemic.

Outcome

With COVID-19 vaccine demand down and no buyer found, BioNTech said in September 2026 that Marburg would close at the start of 2028 and that Pfizer would take over all Comirnaty manufacturing.

Source →

Neon Therapeutics

2020

$67M

Why

BioNTech acquired the Cambridge, Massachusetts neoantigen T-cell therapy company in an all-stock deal to add a U.S. R&D presence and neoantigen expertise.

Impact

Neon became BioNTech US, the company's U.S. research hub.

Outcome

The Cambridge site remains part of BioNTech's U.S. operations.

Source →

BioNTech SE's Growth & Acquisition Strategy

BioNTech's stated goal is to become a multi-product oncology company by 2030. The plan rests on three groups of medicines: next-generation immunomodulators led by pumitamig, now in seven pivotal trials across lung, breast, colorectal and gastric cancer, and gotistobart; antibody-drug conjugates such as trastuzumab pamirtecan (HER2) and elfetabart drozuntecan (B7-H3), which has been given to more than 1,000 patients; and mRNA cancer immunotherapies including autogene cevumeran with Genentech. It is testing these assets together in more than ten novel-novel combinations, cutting non-focus programs, and handing all COVID-19 vaccine manufacturing to Pfizer to free cash for the clinic. Next-generation mRNA platform work is to be contributed to the founders' new company.

How BioNTech SE Makes Money

BioNTech earns most of its revenue from Comirnaty. In most markets Pfizer sells the vaccine and the two companies split gross profit 50:50, so BioNTech books only its share; in Germany BioNTech records direct sales as revenue, and Fosun Pharma holds rights in Greater China. The second revenue line is partnerships: Bristol Myers Squibb paid $1.5 billion upfront in 2025 for a 50:50 share of pumitamig and owes $2 billion in non-contingent anniversary payments through 2028, and BioNTech expects to recognize ~$693 million (€613 million) of BMS collaboration revenue in Q3 2026. Smaller amounts come from a pandemic-preparedness contract with the German government and service businesses. The long-term plan is to sell its own cancer medicines, which is why sales and marketing spending is rising ahead of planned launches.

BioNTech Acquisitions FAQ

When did BioNTech acquire artificial intelligence company InstaDeep?

BioNTech agreed in January 2023 to buy London-based AI company InstaDeep for about $478 million (£362 million) in cash and BioNTech shares upfront, plus up to about $264 million (£200 million) in milestones, to bring machine learning into neoantigen prediction and drug design.

When did BioNTech acquire Biotheus and what assets did it gain?

In November 2024, BioNTech announced the acquisition of clinical-stage biotechnology company Biotheus for up to $950 million ($800 million upfront), gaining full global rights to PM8002 (BNT327), a late-stage bispecific antibody targeting PD-L1 and VEGF-A in solid tumors.

What manufacturing facility did BioNTech acquire from Novartis in Marburg?

In September 2020 BioNTech bought Novartis's biologics plant in Marburg, Germany, and converted it to mRNA production for Comirnaty. In September 2026 it said Marburg would close at the start of 2028 after no buyer was found.

When did BioNTech acquire Neon Therapeutics in the United States?

In May 2020, BioNTech acquired Cambridge, Massachusetts-based Neon Therapeutics in an all-stock transaction valued at approximately $67 million, strengthening its US clinical development presence and neoantigen T-cell targeting capabilities.

What cell therapy assets did BioNTech acquire from Kite Pharma / Gilead in 2021?

In July 2021, BioNTech acquired Kite Pharma's solid tumor TCR (T-cell receptor) clinical development platform and its state-of-the-art manufacturing facility in Gaithersburg, Maryland, to accelerate its US cell therapy clinical trials.

What clinical licensing agreements did BioNTech execute with DualityBio?

In 2023, BioNTech partnered with DualityBio, paying $170 million upfront and committing up to $1.5 billion in milestones to acquire global co-development rights to multiple clinical-stage antibody-drug conjugates (DB-1303/BNT323 and DB-1311/BNT324).

What did BioNTech acquire from MAB Discovery?

In 2019 BioNTech acquired the antibody generation unit and automated discovery platform of MAB Discovery in Bavaria, Germany, to speed up monoclonal antibody discovery.

Why did BioNTech buy CureVac?

BioNTech bought its Tübingen-based mRNA rival in an all-stock deal that closed on December 18, 2025, months after settling U.S. patent litigation with CureVac and GSK. The deal brought CureVac's mRNA know-how and patents in-house.

What companies has BioNTech acquired?

Using its massive vaccine windfall, BioNTech famously acquired the artificial intelligence startup InstaDeep for roughly $680 million to aggressively integrate advanced machine learning into its drug discovery process.

Related M&A Histories

Compare corporate acquisition records, deal values, and strategic targets

Competitor

Moderna

View M&A Histories
Competitor

Pfizer

View M&A Histories
Competitor

Merck

View M&A Histories
Competitor

Astrazeneca

View M&A Histories
Competitor

Gilead Sciences

View M&A Histories
Competitor

Bristol Myers Squibb

View M&A Histories

Explore BioNTech

Core profile pages, founders and related research hubs for this company.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.